Abhishek Srivastava
Plus aucun poste en cours
Fortune : 145 $ au 31/03/2024
Profil
Abhishek Srivastava worked as the Vice President-Cell Therapy Development at Athenex, Inc. He then served as the Vice President-Technical Operations at Alaunos Therapeutics, Inc. Dr. Srivastava holds a doctorate degree from the University of Louisville School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/03/2023 | 80 ( 0,00% ) | 145 $ | 31/03/2024 |
Anciens postes connus de Abhishek Srivastava
| Sociétés | Poste | Fin |
|---|---|---|
| ALAUNOS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/10/2023 |
| ATHENEXPAR | Corporate Officer/Principal | - |
Formation de Abhishek Srivastava
| University of Louisville School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ALAUNOS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Athenex, Inc.
 Athenex, Inc. Pharmaceuticals: MajorHealth Technology Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY. | Health Technology |
